Heparin Market Size, Share, and Trends 2025 to 2034

What is the Heparin Market Size?

The global heparin market size accounted for USD 6.05 billion in 2024 and is expected to exceed around USD 10.21 billion by 2034, growing at a CAGR of 5.37% from 2025 to 2034.

AI in the Market

AI is transforming the heparin market in three main areas: manufacturing, drug development, and patient management. AI not only automates production but also controls quality, and importantly, drives the company toward zero production errors. In drug discovery, AI accelerates the identification of new heparin therapies through predictive algorithms, rather than relying solely on trial and error. For instance, AI helps healthcare providers deliver personalized medicine by adjusting heparin dosages based on patient data, thereby improving safety and outcomes. AI also enables healthcare professionals to monitor patients in real-time during anticoagulant treatments. In logistics, AI predicts demand first and then reduces waste, making the supply chain more efficient. Additionally, AI-powered market intelligence tools analyze data to develop pricing and distribution strategies, ultimately enhancing market efficiency and access.

U.S. Heparin Market Size and Growth 2025 to 2034

The U.S. heparin market size reached was exhibited at USD 2.34 billion in 2024 and is projected to be worth around USD 4.10 billion by 2034, growing at a CAGR of 5.77% from 2025 to 2034.

North America has garnered the largest share in 2024. The growth of the heparin market in the North America region is being driven by rising incidences of cardiovascular disorders. As per the Centers for Disease Control and Prevention, approximately 12.1 million people in the U.S. will have atrial fibrillation by 2034. In addition, growing healthcare expenditure as well as expansion of healthcare industry are also driving the North America heparin market. The North America region was valued at USD 2.6 billion in 2024.

Asia-Pacific is expected to develop at the fastest rate during the forecast period. China and India dominated the heparin market in Asia-Pacific region. The Asia-Pacific heparin market growth is attributed to the expansion of healthcare infrastructure. The other factors such as adoption of technologically advanced products, growing initiatives by government, and rising patient population are contributing towards the growth of Asia-Pacific heparin market.

Heparin Market Growth Factors

One of the significant factors driving the growth of global heparin market is rising incidences of cardiovascular and venous thromboembolism. Deep vein thrombosis and pulmonary embolism harm around 900,000 people in the U.S. each year, as per the data published by the Centers for Disease Control and Prevention in 2018. This is expected to drive demand for heparin in the global market.

Another factor boosting the growth of global heparin market is rising geriatric population. The geriatric population is more vulnerable to various disorders such as orthopedic disorders and arthritis. In 2021, for example, it was anticipated that more over 350 million individuals worldwide had arthritis. As a result, the growing number of senior people suffering from orthopedic diseases drives up demand for surgical treatment, propelling the industry forward. Thus, this factor is supporting the growing demand for heparin in the market over the forecast period.

The COVID-19 pandemic was said to have had a positive influence on the global heparin market, boosting upper income for number of major players operating in healthcare sector. Furthermore, as the number of people infected with COVID-19 grows, so does the demand for heparin, which helps to control the symptoms of respiratory infections while also thinning the blood.

The technologically sophisticated products, regulatory approvals, and the launch of new products, cooperation agreement, and acquisition with other market players are all priorities for key competitors in the worldwide heparin market. These methods are likely to propel the global heparin industry forward. The government all around the world are collaborating with major market players for the growth and development of global heparin market. In addition, the government is also heavily investing in the launch of new products, which is contributing towards the global heparin market.

• The number of cardiovascular and thromboembolic disorder cases is increasing steadily, which in turn is leading to a higher demand for heparin therapies.
  
• The population of elderly people, who are more prone to getting orthopedic and circulatory conditions, is one of the main factors driving the need for anticoagulant treatments.
  
• The development of products through continuous innovations, better formulations, and the entry of biosimilar heparin products are all contributing to the increase in therapeutic outcomes.
  
• The pharmaceutical companies' strategic collaborations and investments, together with the government's initiatives, are making research on heparin and its global accessibility easier.
  
• Supportive regulations and approvals for advanced formulations are giving a boost to product portfolios and are also encouraging market expansion.
  

Market Scope 

Type Insights

The low molecular weight segment accounted largest revenue share in 2023. The growth of the low molecular weight segment is being driven by growing adoption of this kind of products globally. In addition, the rising product launch by market players is driving the growth of segment. The introduction of low molecular weight heparin products to the global heparin market. For example, Valeo Pharma Inc., reported in November 2019 that they had submitted a new drug submission for a low molecular weight heparin biosimilar to Health Canada, which had been accepted for review.

The ultra-low molecular weight segment is fastest growing segment from 2024 to 2033. The growth of the ultra-low molecular weight is attributed to the launch of products with increased pharmacological properties.

Route of Administration Insights

The subcutaneous segment dominated the heparin market in 2023. The growth of the subcutaneous segment is being driven by the growing adoption of low molecular weight heparin. The subcutaneous route of administration is a low-cost process that is carried out in hospitals.

The intravenous segment is fastest growing segment over the forecast period. It comprises a few of unfractioned heparin’s most well-known intravenous product lines. The intravenous route of administration is widely adopted by healthcare practitioners.

Application Insights

The coronary artery disease segment has garnered highest market share in 2023. The growth of the segment is attributed to the rising prevalence of heart disorders. As per the American Heart Association, around 92.1 million American adults suffered from cardiovascular disease in 2018. Furthermore, cardiovascular disease is responsible for around one in every three deaths in the U.S., responsible for roughly 2,300 deaths per day.

The venous thromboembolism segment is expected to hit strong growth from 2024 to 2033. One of the key elements driving the growth of segment is increased awareness of thrombosis. The International Society on Thrombosis and Haemostasias, Inc. for example, has launched an online portal to raise thrombosis awareness among patients.

End Use Insights

The hospitals & ambulatory surgical centers segment dominated the heparin market in 2023. This is mostly due to an increased reliance on health care experts for product prescriptions and proper administration, particularly via intravenous infusion. In addition, growing hospital visits is also driving the growth of the segment.

Theclinics segment is fastest growing segment of the heparin market in 2023. Due to many of these medications are provided at dialysis clinics, among other places, the clinics category is predicted to account for highest market share in the global heparin market over the projected period.

Key Developments

• Fresenius Kabi declared 2 new presentations of heparin sodium in comfortable, ready to administer Freeflex IV bags in the U.S. in April 2021. In 2018, Fresenius Kabi introduced heparin sodium in ready to administer non DEHP Freeflex bags, expanding the firm’s critical care portfolio.
•  Meitheal Pharmaceuticals stated in February 2020 that the Food and Drug Administration had approved extra manufacturing capacity and future facility expansion plans for the manufacture of Heparin Sodium Injection, USP.
•  B. Braun Medical Inc. introduced Heparin Sodium Injection, USP in April 2019, the first Heparin 5,000 USP Unit/0.5 ml prefilled syringe with attached safety needle for intravenous and subcutaneous usage in the U.S.
•  Amphastar Pharmaceuticals Inc. gained Food and Drug Administration approval for semi-purified heparin at Amphastar Nanjing Pharmaceuticals and the manufacture of heparin sodium USP at International Medication Systems, Ltd. in June 2018. By enhancing its product offerings, the corporation was able to add value to its business portfolio.
•  The U.S. Food and Drug Administration granted Mylan approval for its Abbreviated New Drug Applications for Heparin Sodium Injection USP, 5,000 USP/mL, 1,000 USP/mL, 10,000 USP/mL, and 20,000 USP/mL, all of which are wrapped in multi-dose vials, in December 2017. 
• In September 2025, Bioiberica will celebrate its 50th anniversary at CPHI Worldwide 2025, launching a new brand identity and website, while exploring innovative applications for heparin molecules with global research partners.
  https://nutraceuticalbusinessreview.com
  
• In July 2025, B. Braun Medical Inc. launched Heparin Sodium Injections in the U.S., enhancing its portfolio with 25,000 Units in 0.45% Sodium Chloride, marking the largest Heparin Premixed bag offering available.
  https://lvb.com/b-braun-launches-largest-u-s-premixed-heparin-line/
  

Value Chain Analysis

• R&D: It is all about the discovery, synthesis, and characterization of heparin compounds first to ensure therapeutic efficacy and then to guarantee biochemical stability.
  Key Players: Pfizer Inc., Sanofi S.A., LEO Pharma A/S, Baxter International Inc.
• Clinical Trials and Regulatory Approvals: The primary focus is on safety testing, efficacy testing, and the process of seeking approval for medical and therapeutic use.
  Key Players: Pfizer, Sanofi, and LEO Pharma
• Formulation and Final Dosage Preparation: This step entails transforming purified heparin into forms that can be injected or otherwise used while maintaining uniformity and sterility.
  Key Players: Baxter International Inc., Fresenius Kabi, and B. Braun
• Packaging and Serialization: Heparin products are packaged in such a way that their quality and authenticity are assured through traceable packaging.
  Key Players: Baxter International Inc., Pfizer Inc., Sanofi
• Distribution to Hospitals, Pharmacies: The responsibility of logistics and cold-chain transport is to deliver the drug in a manner that is both efficient and compliant.
  Key players: McKesson, AmerisourceBergen, and Cardinal Health
• Patient Support and Services: Patient education, dosage monitoring, and post-treatment support are some of the ways that therapeutic compliance and outcomes are improved.
  Key Players: Sanofi and LEO Pharma

Heparin Market Companies

• GlaxoSmithKline plc
• Pfizer, Inc.
• Baxter
• Leo Pharma A/S
• Sanofi
• Dr. Reddy’s Laboratories Ltd.
• Aspen Holdings
• B. Braun Medical Inc.
• Fresenius SE & Co. KGaA
• Teva Pharmaceutical Industries Ltd.

Segments Covered in the Report

By Type

• Low Molecular Weight Heparin
• Ultra-low Molecular Weight Heparin
• Unfractionated Heparin

By Route of Administration

• Intravenous
• Subcutaneous

By Packaging

• Glass
• Plastic

By Container

• Bottles
• Bags
• Vials
• Others

By Therapeutics

• Cardiovascular
• Respiratory
• Oncology
• Nephrology
• CNS
• Others

By Treatment

• Deep Vein Thrombosis
• Pulmonary Embolism
• Arterial Thromboembolism
• Others

By Availability

• Raw
• Processed

By Application

• Venous Thromboembolism
• Atrial Fibrillation
• Renal Impairment
• Coronary Artery Disease
• Others

By Source

• Bovine
• Porcine

By Ingredients

• Sodium
• Calcium
• Others

By Strength

• 10 Unit
• 100 Unit
• 1000 Unit
• 5000 Unit
• 10000 Unit
• 25000 Unit
• Others

By End Use

• Hospitals
• Clinics
• Homecare
• Ambulatory Surgical Centres
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy and Drug Store
• Online Pharmacy
• Others

By Geography

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Malaysia
• Philippines
• Latin America
• Brazil
• Rest of Latin America
• Middle East & Africa (MEA)
• GCC
• North Africa
• South Africa
• Rest of the Middle East & Africa